We are live on ! Find out more
CM

Crestline Management Portfolio holdings

AUM $53.5M
1-Year Est. Return 80.67%
This Fund
S&P 500
This Quarter Est. Return
+9.02%
1 Year Est. Return
+80.67%
3 Year Est. Return
+80.2%
5 Year Est. Return
+49.87%
10 Year Est. Return
+446.13%
AUM
$62.6M
AUM Growth
-$673K
Cap. Flow
-$4.99M
Cap. Flow %
-7.97%
Top 10 Hldgs %
100%
Holding
3
New
–
Increased
–
Reduced
2
Closed
–

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
DNLI icon
Denali Therapeutics
DNLI
+$4.22M
2
SANA icon
Sana Biotechnology
SANA
+$763K

Sector Composition

Rank Sector Weight
1 Healthcare 96.9%
2 Technology 3.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DNLI icon
1
Denali Therapeutics
DNLI
$3.84B
$54M 86.33%
3,860,732
-300,000
-7% -$4.22M
SANA icon
2
Sana Biotechnology
SANA
$1.18B
$6.61M 10.56%
2,420,937
-370,000
-13% -$763K
EGHT icon
3
8x8 Inc
EGHT
$287M
$1.94M 3.1%
990,580
– –

Similar funds

OM
OV Management Minneapolis, Minnesota $53.5M AUM 5.46% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $53.5M AUM 26.99% 1-Year Est. Return
HCM
Harspring Capital Management New York $53.7M AUM 23.29% 1-Year Est. Return
ETCM
Evolutionary Tree Capital Management Alexandria, Virginia $53M AUM 24.7% 1-Year Est. Return
IDBONY
Israel Discount Bank of New York New York $54M AUM 13.02% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $52.9M AUM 2.04% 1-Year Est. Return
TCDRS
Texas County & District Retirement System Austin, Texas $54.6M AUM 22.55% 1-Year Est. Return
FPAM
Feynman Point Asset Management New York $54.7M AUM

Crestline Management's Q2 2025 Portfolio in Review

As of Q2 2025, Crestline Management held 3 positions worth $62.6M, down 1.1% from $63.2M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Crestline Management withdrew a net $4.99M in Q2 2025, reducing 2 holdings. Its largest reduction was Denali Therapeutics, cutting an estimated $4.22M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 97% a quarter earlier, followed by Technology.

  • Crestline Management's biggest Q2 2025 reduction was Denali Therapeutics, cutting an estimated $4.22M.
  • Crestline Management's ten largest holdings make up 100% of its $62.6M portfolio in Q2 2025.
  • Crestline Management opened 0 new positions and closed 0 in Q2 2025.
  • Crestline Management's portfolio value fell 1.1% quarter-over-quarter to $62.6M.

Based on Crestline Management's 13F filing for Q2 2025, filed 14 Aug 2025.